JadiCells, the investigative stem cell therapy of Therapeutic Solutions International (TSOI), retained lung function and increased the number of cells thought to play a role in lung repair in mice with inflammation-induced lung damage, the company announced.
These preclinical findings further support JadiCell’s potential to both prevent excessive inflammation and lung damage and also repair established lung tissue damage seen in chronic lung diseases such as. chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
TSOI filed a patent last year covering the therapeutic use of JadiCells and its multiple combinations in COPD. The treatment is currently being tested in clinical trials to treat severe COVID-19 and has shown promising results.
“As we are completing the preparations for the start of our Phase 3 COVID-19 Lung Failure clinical trial, I am proud to report that significant fundamental scientific progress is being made, which forms the basis for possible extension to COPD and IPF, which represents a significantly unmet medical need, ”said Timothy Dixon, TSOI President and CEO, in a Press release.
“Based on my medical experience, the currently published data on JadiCells, and what I have personally observed from administration during Right to try exception, I think these cells represent a paradigm shift in the way we approach lung disease, ”said James Veltmeyer, MD, TSOI’s Chief Medical Officer.
JadiCells comprise a type of mesenchymal stem cells (MSCs) derived from cells that line the umbilical cord. MSCs are adult stem cells that are present in various tissues – including the umbilical cord, bone marrow and adipose tissue – that can both self-renew and mature into many other cell types.
They are gaining increasing interest as a potential therapeutic approach to a variety of conditions due to their strong immunosuppressive, anti-inflammatory, neuroprotective and regenerative properties.
Compared to other stem cells, JadiCells are thought to produce larger amounts of certain therapeutic factors and can be stimulated in various ways to increase their regenerative properties, according to TSOI.
COPD is characterized by excessive airway inflammation, remodeling of lung tissue and the progressive destruction of the alveoli, the small air sacs responsible for gas exchange. This is associated with the death of alveolar epithelial cells lining the alveoli and a reduced capacity of alveolar epithelial cells to counteract this defect.
JadiCells have previously been shown to be superior to stem cells obtained from other sources to reduce lung damage in a mouse model of emphysema, a severe form of COPD.
Stem cell therapy can regulate inflammatory responses in the lungs by reducing the levels of the pro-inflammatory molecule TLR4 and increasing the levels of MerTK, an anti-inflammatory protein, according to data.
These results support JadiCells’ therapeutic potential in COPD and other lung diseases.
“The field of cell therapy is the future of medicine, but to maximize their potential benefits, we should always strive to learn as much about their science as possible,” said Thomas Ichim, PhD, board member of TSOI.
“TSOI in my opinion is unique because we follow science instead of trying to force science to fit into a narrative,” Ichim added.